{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:32:18Z","timestamp":1770960738552,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bausch Health US, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12325-022-02090-9","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:03:37Z","timestamp":1647497017000},"page":"2178-2191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department"],"prefix":"10.1007","volume":"39","author":[{"given":"W. Frank","family":"Peacock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Slatkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"3","key":"2090_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S2468-1253(18)30008-6","volume":"3","author":"AD Farmer","year":"2018","unstructured":"Farmer AD, Holt CB, Downes TJ, et al. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol. 2018;3(3):203\u201312. https:\/\/doi.org\/10.1016\/S2468-1253(18)30008-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"2090_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/2050640618786145","volume":"6","author":"V Andresen","year":"2018","unstructured":"Andresen V, Banerji V, Hall G, et al. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroenterol J. 2018;6(8):1254\u201366. https:\/\/doi.org\/10.1177\/2050640618786145.","journal-title":"United Eur Gastroenterol J"},{"issue":"9","key":"2090_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","volume":"36","author":"CE Argoff","year":"2020","unstructured":"Argoff CE. Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting mu-opioid receptor antagonists. Clin J Pain. 2020;36(9):716\u201322. https:\/\/doi.org\/10.1097\/AJP.0000000000000852.","journal-title":"Clin J Pain"},{"issue":"1","key":"2090_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35\u201342. https:\/\/doi.org\/10.1111\/j.1526-4637.2008.00495.x.","journal-title":"Pain Med"},{"issue":"3","key":"2090_CR5","first-page":"160","volume":"9","author":"AW Fernandes","year":"2016","unstructured":"Fernandes AW, Kern DM, Datto C, et al. Increased burden of healthcare utilization and cost associated with opioid-related constipation among patients with noncancer pain. Am Health Drug Benefits. 2016;9(3):160\u201370.","journal-title":"Am Health Drug Benefits."},{"issue":"2","key":"2090_CR6","first-page":"79","volume":"10","author":"T Olufade","year":"2017","unstructured":"Olufade T, Kong AM, Princic N, et al. Comparing healthcare utilization and costs among Medicaid-insured patients with chronic noncancer pain with and without opioid-induced constipation: a retrospective analysis. Am Health Drug Benefits. 2017;10(2):79\u201386.","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"2090_CR7","first-page":"93","volume":"8","author":"Y Wan","year":"2015","unstructured":"Wan Y, Corman S, Gao X, et al. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. Am Health Drug Benefits. 2015;8(2):93\u2013102.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"2090_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/pm\/pny151","volume":"20","author":"AH Vallerand","year":"2019","unstructured":"Vallerand AH, Hendry S, Baldys E, et al. Analysis of patient-provider interactions regarding the burden and treatment of opioid-induced constipation in adults with chronic noncancer pain. Pain Med. 2019;20(5):889\u201396. https:\/\/doi.org\/10.1093\/pm\/pny151.","journal-title":"Pain Med"},{"issue":"12","key":"2090_CR9","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/pme.12937","volume":"16","author":"CE Argoff","year":"2015","unstructured":"Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324\u201337. https:\/\/doi.org\/10.1111\/pme.12937.","journal-title":"Pain Med"},{"key":"2090_CR10","doi-asserted-by":"crossref","unstructured":"Caffrey J, Pensa G. Who gets constipation? What are the causes? What is an evidence-based approach management? In: Graham A, Carlberg DJ, editors. Gastrointestinal emergencies. Cham: Springer; 2019. p. 185\u2013187.","DOI":"10.1007\/978-3-319-98343-1_53"},{"key":"2090_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/IJGM.S44417","volume":"6","author":"G Niv","year":"2013","unstructured":"Niv G, Grinberg T, Dickman R, et al. Perforation and mortality after cleansing enema for acute constipation are not rare but are preventable. Int J Gen Med. 2013;6:323\u20138. https:\/\/doi.org\/10.2147\/IJGM.S44417.","journal-title":"Int J Gen Med"},{"issue":"10","key":"2090_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/pm\/pnw255","volume":"18","author":"S Muller-Lissner","year":"2017","unstructured":"Muller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837\u201363. https:\/\/doi.org\/10.1093\/pm\/pnw255.","journal-title":"Pain Med"},{"key":"2090_CR13","unstructured":"Salix Pharmaceuticals, Inc. Highlights of Prescribing Information: RELISTOR (methylnaltrexone bromide). 2020;1\u201353."},{"issue":"7","key":"2090_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/jpm.2014.0362","volume":"18","author":"J Bull","year":"2015","unstructured":"Bull J, Wellman CV, Israel RJ, et al. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593\u2013600. https:\/\/doi.org\/10.1089\/jpm.2014.0362.","journal-title":"J Palliat Med"},{"issue":"1","key":"2090_CR15","first-page":"33","volume":"36","author":"JL Watkins","year":"2011","unstructured":"Watkins JL, Eckmann KR, Mace ML, et al. Utilization of methylnaltrexone (Relistor) for opioid-induced constipation in an oncology hospital. P T. 2011;36(1):33\u20136.","journal-title":"P T"},{"issue":"1","key":"2090_CR16","first-page":"39","volume":"7","author":"N Slatkin","year":"2009","unstructured":"Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39\u201346.","journal-title":"J Support Oncol"},{"issue":"22","key":"2090_CR17","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"J Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332\u201343. https:\/\/doi.org\/10.1056\/NEJMoa0707377.","journal-title":"N Engl J Med"},{"issue":"5","key":"2090_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/jgh.14586","volume":"34","author":"K Nishie","year":"2019","unstructured":"Nishie K, Yamamoto S, Yamaga T, et al. Peripherally acting mu-opioid antagonist for the treatment of opioid-induced constipation: systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34(5):818\u201329. https:\/\/doi.org\/10.1111\/jgh.14586.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2090_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v054.i07","volume":"54","author":"J Hainmueller","year":"2013","unstructured":"Hainmueller J, Xu Y. ebalance: a stata package for entropy balancing. J Stat Softw. 2013;54(7):1\u201318.","journal-title":"J Stat Softw"},{"key":"2090_CR20","unstructured":"Bureau of Labor Statistics. Consumer Price Index 2020. https:\/\/www.bls.gov\/cpi\/tables\/supplemental-files\/home.htm. Accessed 12 July 2021."},{"issue":"3","key":"2090_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/00325481.2016.1149017","volume":"128","author":"N Mehta","year":"2016","unstructured":"Mehta N, O\u2019Connell K, Giambrone GP, et al. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016;128(3):282\u20139. https:\/\/doi.org\/10.1080\/00325481.2016.1149017.","journal-title":"Postgrad Med"},{"issue":"3","key":"2090_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mayocp.2011.11.014","volume":"87","author":"SB Sawh","year":"2012","unstructured":"Sawh SB, Selvaraj IP, Danga A, et al. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc. 2012;87(3):255\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.014.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2090_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1365-2036.2010.04244.x","volume":"31","author":"SR Earnshaw","year":"2010","unstructured":"Earnshaw SR, Klok RM, Iyer S, et al. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness\u2013a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010;31(8):911\u201321. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04244.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"2090_CR24","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2018.18472","volume":"320","author":"JW Busse","year":"2018","unstructured":"Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448\u201360. https:\/\/doi.org\/10.1001\/jama.2018.18472.","journal-title":"JAMA"},{"issue":"4","key":"2090_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5055\/jom.2015.0282","volume":"11","author":"S Gupta","year":"2015","unstructured":"Gupta S, Patel H, Scopel J, et al. Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey. J Opioid Manag. 2015;11(4):325\u201338. https:\/\/doi.org\/10.5055\/jom.2015.0282.","journal-title":"J Opioid Manag"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02090-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:22:46Z","timestamp":1651303366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02090-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}